Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-20

Study Completion Date

2023-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, doble blind, placebo controlled clinical trial to asses de safety and efficacy of intravenous administration of alogenic adipose tissue-derived mesenchymal stem cells in the first four days from acute ischemic stroke.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial

NCT01678534

Ischemic Stroke

COMPLETED PHASE2

Methylprednisolone for Stroke With Large Infarct Core and Post-stroke Lymphocytopenia

NCT07202143

Large Infarct Core Post-stroke Lymphocytopenia

RECRUITING PHASE3

Intra-arterial Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke

NCT02178657

Ischemic Stroke

COMPLETED PHASE2

Mesenchymal Stromal Cells for Ischemic Stroke

NCT01922908

Ischemic Stroke

WITHDRAWN PHASE1/PHASE2

Study to Examine the Effects of MultiStem in Ischemic Stroke

NCT01436487

Ischemic Stroke

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Two spanish hospitals with teams experienced in stroke management will participate in this study, recruiting a total of 30 patients between them both. After confirming that patients fulfill the inclusion criteria and none of the exclusion criteria, informed consent will be signed and randomization will take place (1:1). There are two different groups of treatment; the first group will be treated with intravenous alogenic adipose tissue-derived stem cells (at a concentration of one million cells per kg) within the first four days from stroke onset, the second group will be treated will an intravenous placebo solution. Follow-up will last for 24 months during which safety issues such as adverse events and neurological and systemic complications will be assessed at 24 hours, 7 days and 3, 6, 12,18 and 24 months after treatment. Neurological disability using the modified Rankin Scale and National Institute of Health Stroke Scale will also be registered in every scheduled visit. Biochemical markers of tissue repair (GM-CSF, BDNF, VEGF, TGF-1, GFAP, MBP, MMP-3) as well as extracellular vesicles will be extracted on baseline visit as well as 7 days and 3 months after treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke Adipose Tissue-derived Stem Cell Functional Status

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two different treatment grupos; intravenous alogenic adipose tissue-derived mesenchymal stem cells or intravenous placebo solution

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Treatment and placebo solutions have identical appearance. Protocols will be designed to ensure that the physician evaluating patient safety and efficacy outcome as well as laboratory analysis, will not have access to the randomisation codes.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

15 patients will receive intravenous alogenic adipose tissue-derived stem cells in a single dose of one million cells per kg.

Group Type EXPERIMENTAL

Alogenic adipose tissue-derived stem cells

Intervention Type OTHER

Concentration of the cells: 10 million cells / ml

Placebo group

15 patients will receive a single intravenous placebo solution with the same appearance as the treatment group.

Group Type PLACEBO_COMPARATOR

Placebo solution

Intervention Type DRUG

Placebo intravenous solution, same appearance stem cells solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alogenic adipose tissue-derived stem cells

Concentration of the cells: 10 million cells / ml

Intervention Type OTHER

Placebo solution

Placebo intravenous solution, same appearance stem cells solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ischemic stroke patients \> 18 years old
* Patients must be able to be treated within the first 4 days (+/- 1) from acute stroke symptoms onset. If the time of symptom onset is unknown, this shall refer to the last time the patient was observed as asymptomatic.
* A computed tomography (CT) or magnetic resonance imaging (MRI) scan compatible with the clinical diagnosis of acute non-lacunar IS in the region of the middle cerebral artery (with cortical or subcortical involvement).
* A score on the National Institute of Health Stroke Scale (NIHSS) of 8-20, with at least two of these points in sections 5 and 6 (motor deficit) at the time of inclusion. NIHSS evaluation for screening of these patients will take place after finalization of reperfusion therapies (if they have been performed) providing that the clinical condition of the patient is stable with no prevision of immediate recovery. A measurable focal neurologic disabilty must persist to the time of treatment.
* A prestroke score on the Modified Rankin Scale (mRS) ≤1 (no significant disability).
* Female subjects non-child bearing potential. Female subjects who are of non-childbearing potential are defined as meeting at least 1 of the following criteria:

Have undergone a documented hysterectomy and/or bilateral oophorectomy; Have medically confirmed ovarian failure; or Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause.

* Female subjects of child-bearing potential need a negative pregnancy test and must agree to use adequate contraception for the duration of the study (from screening through the final of the study). The following types of contraception are considered adequate provided they are locally authorized for use: oral, transdermal, or injectable (depot) estrogen and/or progestogen, selective estrogen receptor modulator therapy, intrauterine contraceptive device, double barrier method (e.g., condom and diaphragm or spermicidal gel) or vasectomy.
* Signed informed consent

Exclusion Criteria

* Comatose patients; patients with a score of 2 or more on item 1a of the NIHSS related to the degree of awareness.
* Current drug or alcohol use or dependence
* Active infectious disease, including human immunodeficiency virus, hepatitis B, and hepatitis C. A controlled infection is not an exclusion criterion.
* Pre-existing dementia.
* A health status, any clinical condition (eg, short life expectancy, and coexisting disease or a surgical or endovascular planned procedure) or other characteristic that precludes appropriate diagnosis, treatment, or follow-up in the trial.
* Patients who are participating in another clinical trial.
* Inability or unwillingness of the individual or their legal guardian/representative to provide written informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No